Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly JG, Fischer MA, Kesselheim AS, Gagne JJ. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLOS Medicine 2019:13 de marzo. [Ref.ID 103076]

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

Anónimo. FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan. FDA U.S. Food and Drug Administration 2019:22 de marzo. [Ref.ID 103071]

Byrd JB, Chertow GM, Bhalla V. Hypertension hot potato — Anatomy of the angiotensin-receptor blocker recalls. N Engl J Med 2019;380:25 de abril. [Ref.ID 103055]

Anónimo. FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall. FDA U.S. Food and Drug Administration 2019:1 de marzo. [Ref.ID 103044]

Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ 2018;363:24 de octubre. [Ref.ID 102866]

Anónimo. FDA inspectors raised red flags at Chinese heart drug maker more than a year before recall. DIA Daily 2018:5. [Ref.ID 102786]

Navarese EP, Robinson JG, Kowatewski M, Kotodziejczak M, Andreotti F, Bliden K, Tantry U, Kubica J, Raggi P, Gurbel PA. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering. A systematic review and meta-analysis. JAMA 2018;319:17 de abril. [Ref.ID 102784]

Navar AM, Peterson ED. Challenges in interpreting the lipid-lowering trials: biology vs ecology. JAMA 2018;319:17 de abril. [Ref.ID 102783]

Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA 2018;319:12 de junio. [Ref.ID 102780]

Anónimo. FDA expands recall of potentially contaminated valsartan. DIA Daily 2018:8 de agosto. [Ref.ID 102753]

Anónimo. EMA says tainted valsartan may cause one additional cancer case in every 5,000 patients taking the drug. DIA Daily 2018:5. [Ref.ID 102738]

AEMPS. Retirada del mercado de algunos lotes de medicamentos que contienen valsartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2018:5 de julio. [Ref.ID 102709]

Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K, on behalf of the show SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018;391:9 de junio. [Ref.ID 102692]

Blankestijn PJ, Bots ML. Renal denervation in uncontrolled hypertension: the story continues to unfold. Lancet 2018;391:9 de junio. [Ref.ID 102690]

Pottegård A, Pedersen SA, Alba S, Schmidt J, Hölmich LR, Friis S, Gaist D. Association of hydrochlorothiazide use and risk of malignant melanoma. JAMA Intern Med 2018;178:1120-2. [Ref.ID 102645]

Patel TK, Patel TB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol 2018;74:junio. [Ref.ID 102626]

Kamali KN, Lloyd-Jones DM, van der Leeuw J, Goff Jr DC, Yusuf S, Zanchetti A, Glasziou P, Jackson R, Woodward M, Rodgers A, Neal BC, Berge E, Teo K, Davis BR, Chalmers J, Pepine C, Rahimi K, Sundström J, on behalf of the Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. PLOS Medicine 2018:20 de marzo. [Ref.ID 102591]

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

Garattini S, Bertele V. Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines. Eur J Clin Pharmacol 2018;74:marzo. [Ref.ID 102550]